Prestigious Recognitions, Product Enhancements, and Earnings Releases - Analyst Notes on Discover, BlackRock, Covance, BioMarin and Vertex

NEW YORK, May 7, 2014 /PRNewswire/ --

Today, Analysts Review released its analysts' notes regarding Discover Financial Services (NYSE: DFS), BlackRock, Inc. (NYSE: BLK), Covance Inc. (NYSE: CVD), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) and Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/2142-100free.

Discover Financial Services Analyst Notes
On April 29, 2014, Discover Financial Services (Discover) - a direct banking and payment services Company, announced that it has been honored for the next generation customer service application. Discover's new technology has been recognized on the 2014 InformationWeek Elite 100 List - a list of the top business technology innovators in the U.S. Commenting on this recognition, Glenn Schneider, Chief Information Officer, Discover, said, "We leveraged leading-edge data analytics and real-time technologies to help us instantly identify, understand and successfully address the needs of our customers." As stated, Discover made the list by developing a new application that provides a fully comprehensive, customer-centric view and supplies account managers with better data and up-to-the-minute information, allowing them to provide superior customer service. The full analyst notes on Discover are available to download free of charge at:

http://www.analystsreview.com/2142-DFS-07May2014.pdf

BlackRock, Inc. Analyst Notes
On April 21, 2014, BlackRock, Inc. (Blackrock) - the world's largest asset manager and owner of iShares family of exchange traded funds, introduced CoRI™ Retirement Suite Enhancements. According to the Company, the new enhanced CoRI Tool illustrates pre-retirees on ways to plan for retirement income. BlackRock's CoRI retirement suite, through a new feature, helps pre-retirees identify savings and investment strategies that can help plan for income goals in retirement. Chip Castille, Head of BlackRock's U.S. Retirement Group, said, "The CoRI approach addresses the crucial issue at the heart of the retirement challenge: saving enough in your working years to get the income you want in retirement. CoRI gives pre-retirees unique insight into the savings-to-income translation - plus the tools to put that insight to work." The full analyst notes on BlackRock are available to download free of charge at:

http://www.analystsreview.com/2142-BLK-07May2014.pdf

Covance Inc. Analyst Notes
On May 2, 2014, shares of Covance Inc. (Covance) declined 6.95%, a day after the Company reported Q1 2014 adjusted EPS, which exceeded analysts' estimates, but trailed expectations on the revenue front. The Company's net revenue for Q1 2014 was $620.1 million, up 6.9% YoY, but lagged Thomson's Reuters analysts' consensus revenue estimate of $632.2 million. Excluding a gain on the sale of our Seattle genomics laboratory of $1.6 million and charges associated with restructuring and other cost reduction actions totaling $4.1 million, the Company reported earnings per diluted share of $0.90, up 20.1% YoY. Thomson Reuters' anticipated the Company to earn $0.89 per share for Q1 2014. According to the Company, it expects additions of a few cents in EPS in each quarter throughout the year and has narrowed its 2014 financial expectations to revenue growth of 6% - 9% and pro forma diluted EPS of $3.70 to $3.95. The full analyst notes on Covance are available to download free of charge at:

http://www.analystsreview.com/2142-CVD-07May2014.pdf

BioMarin Pharmaceutical Inc. Analyst Notes
On May 1, 2014, BioMarin Pharmaceutical Inc. (BioMarin) announced financial results for Q1 2014. The Company announced net product revenues of $149 million up 17.0% YoY. BioMarin narrowed down its non-GAAP net loss to $0.01 per diluted share for Q1 2014, compared to a non-GAAP net loss of $0.07 per diluted share in Q1 2013. Average analysts from Thomson Reuters expected the Company to report a loss of $0.46 per share for Q1 2014. According to BioMarin, the Company was able to curtail its losses in Q1 2014, due to strong revenue growth across the commercial product portfolio, partially off-set by increased selling, general and administrative expenses, including costs associated with VIMIZIM launch activities, as well as increased research and development expenses. The full analyst notes on BioMarin are available to download free of charge at:

http://www.analystsreview.com/2142-BMRN-07May2014.pdf

Vertex Pharmaceuticals Incorporated Analyst Notes
On May 1, 2014, Vertex Pharmaceuticals Incorporated (Vertex) reported consolidated financial results for Q1 2014 and provided key business updates. Vertex reported Q1 2014 GAAP revenues of $118.5 million as compared to $328.4 YoY. Total adjusted revenues excluding hepatitis C revenues and royalties, for the quarter were $108.2 million, of which KALYDECO contributed $99.5 million. Non-GAAP net loss was $151.4 million, or $0.65 per diluted share, compared to a non-GAAP net income of $5.7 million, or $0.03 per diluted share, during Q1 2013. Analysts polled by Thomson Reuters' expected the Company to report a loss of 68 cents a share on revenue of $134.36 million for Q1 2014. The full analyst notes on Vertex are available to download free of charge at:

http://www.analystsreview.com/2142-VRTX-07May2014.pdf

--
About Analysts Review
We do things differently. Our goal is to provide the best content to our exclusive membership. We are constantly hiring researchers, writers, editors and analysts to add to our team and become better than yesterday. If being a part of a fast growing community with an edge in today's market sounds interesting to you, then sign-up today and experience the full benefits of membership.

EDITOR'S NOTES:

1. This is not company news. We are an independent source and our views do not reflect the companies mentioned.

2. Information in this release is produced on a best efforts basis by Rohit Tuli, a CFA charterholder. The content is then further fact checked and reviewed by an outsourced research provider. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.

3. This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.

4. If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco [at] http://www.analystsreview.com.

5. For any urgent concerns or inquiries, please contact us at compliance [at] http://www.analystsreview.com.

6. Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research [at] http://www.analystsreview.com for consideration.

COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Analysts Review whatsoever for any direct, indirect or consequential loss arising from the use of this document. Analysts Review expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Analysts Review does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Analysts Review

WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?

440k+
Newsrooms &
Influencers

9k+
Digital Media
Outlets

270k+
Journalists
Opted In

GET STARTED